Sanofi and its top-selling Lantus may have bought some time last month with a legal wrench in Eli Lilly’s spokes, but now Merck has bulldozed its way into the conversation with plans to kick off late-stage studies for its own knockoff of the blockbuster drug, further complicating an already heated fight.

…read more

Source: Merck takes aim at Sanofi with a Lantus biosimilar of its own


0 No comments